Loading…

Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity

1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 1980-10, Vol.69 (10), p.1198-1202
Main Authors: Ellis, K.O., Wessels, F.L., Burns, R.H., Pong, S.F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43
cites cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43
container_end_page 1202
container_issue 10
container_start_page 1198
container_title Journal of pharmaceutical sciences
container_volume 69
creator Ellis, K.O.
Wessels, F.L.
Burns, R.H.
Pong, S.F.
description 1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.
doi_str_mv 10.1002/jps.2600691021
format article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jps_2600691021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915434215</els_id><sourcerecordid>JPS2600691021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</originalsourceid><addsrcrecordid>eNqFkM1vFCEYh4nR1LV69WYyxzZZtjB8DHO0jbY1TW2ixiNh4R2XOjtMgG473v2_xU5T48F44SX8PsL7IPSakhUlpD66HtOqloTIlpKaPkELKmqCJaHNU7Qohhozwdvn6EVK16TYiBB7aE9SIhtKF-jn1cbErbGhD9-mKnQVxQdsybHzdtOHGNYw_Jj6Q1zelmIpcYYczWZyMeD6gJ4d4nGKfutdGGBZmWoIO-grM2TvYIyQUrlWNmzHcDO46tbnzb1ohjsPeaqMzX7n8_QSPetMn-DVw9xHX96_-3xyhi8-np6fvL3AlvGaYt5ZYzgRresasWYclAKmuFGNFJTZTpm6tYzyVqi1soTxchhnTA2ENcxyto9Wc6-NIaUInR7L702cNCX6N05dcOo_OEvgzRwYb9ZbcI_2B35Fb2f91vcw_adNf7j69Fc3nrM-Zbh7zJr4XcuGNUJ_vTzV7TFVihCmZfGr2Q-F0M5D1Ml6GCw4H8Fm7YL_1xq_ALmlooA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><source>Wiley-Blackwell Journals</source><creator>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</creator><creatorcontrib>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</creatorcontrib><description>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600691021</identifier><identifier>PMID: 6106711</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo ; 4-Dichlorobenzyl) - 3 ; 6-tetrahydro-2(1H)-pyrimidone ; 6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity ; Animals ; Anti-Anxiety Agents ; Antidepressive Agents ; Brain Chemistry - drug effects ; Cats ; CNS activity-1- ; CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo ; evaluation of antidepressant and antianxiety activity ; Female ; Histamine H1 Antagonists ; Humans ; in vitro and in vivo ; Lethal Dose 50 ; Male ; Mice ; Monoamine Oxidase Inhibitors ; Neurotransmitter Agents - metabolism ; Nictitating Membrane - drug effects ; Parasympatholytics ; Pentylenetetrazole - antagonists &amp; inhibitors ; Pyrimidinones - pharmacology ; Rats ; Stereotyped Behavior - drug effects ; Tetrabenazine - antagonists &amp; inhibitors</subject><ispartof>Journal of pharmaceutical sciences, 1980-10, Vol.69 (10), p.1198-1202</ispartof><rights>1980 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1980 Wiley‐Liss, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</citedby><cites>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600691021$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600691021$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6106711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ellis, K.O.</creatorcontrib><creatorcontrib>Wessels, F.L.</creatorcontrib><creatorcontrib>Burns, R.H.</creatorcontrib><creatorcontrib>Pong, S.F.</creatorcontrib><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</description><subject>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo</subject><subject>4-Dichlorobenzyl) - 3</subject><subject>6-tetrahydro-2(1H)-pyrimidone</subject><subject>6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity</subject><subject>Animals</subject><subject>Anti-Anxiety Agents</subject><subject>Antidepressive Agents</subject><subject>Brain Chemistry - drug effects</subject><subject>Cats</subject><subject>CNS activity-1-</subject><subject>CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo</subject><subject>evaluation of antidepressant and antianxiety activity</subject><subject>Female</subject><subject>Histamine H1 Antagonists</subject><subject>Humans</subject><subject>in vitro and in vivo</subject><subject>Lethal Dose 50</subject><subject>Male</subject><subject>Mice</subject><subject>Monoamine Oxidase Inhibitors</subject><subject>Neurotransmitter Agents - metabolism</subject><subject>Nictitating Membrane - drug effects</subject><subject>Parasympatholytics</subject><subject>Pentylenetetrazole - antagonists &amp; inhibitors</subject><subject>Pyrimidinones - pharmacology</subject><subject>Rats</subject><subject>Stereotyped Behavior - drug effects</subject><subject>Tetrabenazine - antagonists &amp; inhibitors</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><recordid>eNqFkM1vFCEYh4nR1LV69WYyxzZZtjB8DHO0jbY1TW2ixiNh4R2XOjtMgG473v2_xU5T48F44SX8PsL7IPSakhUlpD66HtOqloTIlpKaPkELKmqCJaHNU7Qohhozwdvn6EVK16TYiBB7aE9SIhtKF-jn1cbErbGhD9-mKnQVxQdsybHzdtOHGNYw_Jj6Q1zelmIpcYYczWZyMeD6gJ4d4nGKfutdGGBZmWoIO-grM2TvYIyQUrlWNmzHcDO46tbnzb1ohjsPeaqMzX7n8_QSPetMn-DVw9xHX96_-3xyhi8-np6fvL3AlvGaYt5ZYzgRresasWYclAKmuFGNFJTZTpm6tYzyVqi1soTxchhnTA2ENcxyto9Wc6-NIaUInR7L702cNCX6N05dcOo_OEvgzRwYb9ZbcI_2B35Fb2f91vcw_adNf7j69Fc3nrM-Zbh7zJr4XcuGNUJ_vTzV7TFVihCmZfGr2Q-F0M5D1Ml6GCw4H8Fm7YL_1xq_ALmlooA</recordid><startdate>198010</startdate><enddate>198010</enddate><creator>Ellis, K.O.</creator><creator>Wessels, F.L.</creator><creator>Burns, R.H.</creator><creator>Pong, S.F.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198010</creationdate><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><author>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo</topic><topic>4-Dichlorobenzyl) - 3</topic><topic>6-tetrahydro-2(1H)-pyrimidone</topic><topic>6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity</topic><topic>Animals</topic><topic>Anti-Anxiety Agents</topic><topic>Antidepressive Agents</topic><topic>Brain Chemistry - drug effects</topic><topic>Cats</topic><topic>CNS activity-1-</topic><topic>CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo</topic><topic>evaluation of antidepressant and antianxiety activity</topic><topic>Female</topic><topic>Histamine H1 Antagonists</topic><topic>Humans</topic><topic>in vitro and in vivo</topic><topic>Lethal Dose 50</topic><topic>Male</topic><topic>Mice</topic><topic>Monoamine Oxidase Inhibitors</topic><topic>Neurotransmitter Agents - metabolism</topic><topic>Nictitating Membrane - drug effects</topic><topic>Parasympatholytics</topic><topic>Pentylenetetrazole - antagonists &amp; inhibitors</topic><topic>Pyrimidinones - pharmacology</topic><topic>Rats</topic><topic>Stereotyped Behavior - drug effects</topic><topic>Tetrabenazine - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ellis, K.O.</creatorcontrib><creatorcontrib>Wessels, F.L.</creatorcontrib><creatorcontrib>Burns, R.H.</creatorcontrib><creatorcontrib>Pong, S.F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ellis, K.O.</au><au>Wessels, F.L.</au><au>Burns, R.H.</au><au>Pong, S.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1980-10</date><risdate>1980</risdate><volume>69</volume><issue>10</issue><spage>1198</spage><epage>1202</epage><pages>1198-1202</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>6106711</pmid><doi>10.1002/jps.2600691021</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 1980-10, Vol.69 (10), p.1198-1202
issn 0022-3549
1520-6017
language eng
recordid cdi_crossref_primary_10_1002_jps_2600691021
source Wiley-Blackwell Journals
subjects 1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo
4-Dichlorobenzyl) - 3
6-tetrahydro-2(1H)-pyrimidone
6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity
Animals
Anti-Anxiety Agents
Antidepressive Agents
Brain Chemistry - drug effects
Cats
CNS activity-1-
CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo
evaluation of antidepressant and antianxiety activity
Female
Histamine H1 Antagonists
Humans
in vitro and in vivo
Lethal Dose 50
Male
Mice
Monoamine Oxidase Inhibitors
Neurotransmitter Agents - metabolism
Nictitating Membrane - drug effects
Parasympatholytics
Pentylenetetrazole - antagonists & inhibitors
Pyrimidinones - pharmacology
Rats
Stereotyped Behavior - drug effects
Tetrabenazine - antagonists & inhibitors
title Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacology%20of%201-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone,%20a%20novel%20antidepressant%20compound%20with%20antianxiety%20activity&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Ellis,%20K.O.&rft.date=1980-10&rft.volume=69&rft.issue=10&rft.spage=1198&rft.epage=1202&rft.pages=1198-1202&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1002/jps.2600691021&rft_dat=%3Cwiley_cross%3EJPS2600691021%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/6106711&rfr_iscdi=true